TrialCancer medicine2021

A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.

Michal Sarfaty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.